Pharmacological inhibition of ANO1 has demonstrated anticancer effects in head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), gastrointestinal stromal tumors, CRC, and NSCLC (Liu et al., 2021; Zhong et al., 2021). Here, ANO1 is linked to colorectal carcinoma.